Thrombotic microangiopathy after liver-small bowel transplant

Abhinav Humar, Jose Jessurun, Harvey L. Sharp, Rainer W G Gruessner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We herein report the first case of immunosuppression-associated thrombotic microangiopathy (TMA) in which an extrarenal graft was primarily affected by the characteristic microvascular lesions. Although TMA is a well-known complication of cyclosporine (CSA) or tacrolimus therapy in renal and extrarenal (liver, heart, lung) transplant recipients, the kidney (transplanted or native) is typically the site primarily affected. We describe a combined liver-small bowel transplant recipient who developed tacrolimus-associated TMA that affected both her transplanted small bowel and her native kidneys. Involvement of the bowel, with evidence of microvascular occlusion on biopsy, led to the development of ischemic mucosal ulcers and eventual bowel perforation. Involvement of the kidney manifested with a doubling of the recipient's baseline serum creatinine level. Significant lowering of the tacrolimus dose resulted in healing of the small bowel ulcers and return to her baseline level of renal function. Therefore, it is important to note that, in transplant recipients, TMA with microvascular occlusion may affect extrarenal sites. In small bowel transplant recipients, the result might be ischemic ulcers in the graft and eventual bowel perforation.

Original languageEnglish (US)
Pages (from-to)600-601
Number of pages2
JournalClinical Transplantation
Volume12
Issue number6
StatePublished - Dec 1998
Externally publishedYes

Fingerprint

Thrombotic Microangiopathies
Transplants
Kidney
Tacrolimus
Liver
Ulcer
Immunosuppression
Cyclosporine
Creatinine
Biopsy
Lung
Transplant Recipients
Serum

Keywords

  • Combined liver-small bowel transplantation
  • Hemolytic uremic syndrome
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Thrombotic microangiopathy after liver-small bowel transplant. / Humar, Abhinav; Jessurun, Jose; Sharp, Harvey L.; Gruessner, Rainer W G.

In: Clinical Transplantation, Vol. 12, No. 6, 12.1998, p. 600-601.

Research output: Contribution to journalArticle

Humar, A, Jessurun, J, Sharp, HL & Gruessner, RWG 1998, 'Thrombotic microangiopathy after liver-small bowel transplant', Clinical Transplantation, vol. 12, no. 6, pp. 600-601.
Humar, Abhinav ; Jessurun, Jose ; Sharp, Harvey L. ; Gruessner, Rainer W G. / Thrombotic microangiopathy after liver-small bowel transplant. In: Clinical Transplantation. 1998 ; Vol. 12, No. 6. pp. 600-601.
@article{7356f49caff147a78944956fd707606e,
title = "Thrombotic microangiopathy after liver-small bowel transplant",
abstract = "We herein report the first case of immunosuppression-associated thrombotic microangiopathy (TMA) in which an extrarenal graft was primarily affected by the characteristic microvascular lesions. Although TMA is a well-known complication of cyclosporine (CSA) or tacrolimus therapy in renal and extrarenal (liver, heart, lung) transplant recipients, the kidney (transplanted or native) is typically the site primarily affected. We describe a combined liver-small bowel transplant recipient who developed tacrolimus-associated TMA that affected both her transplanted small bowel and her native kidneys. Involvement of the bowel, with evidence of microvascular occlusion on biopsy, led to the development of ischemic mucosal ulcers and eventual bowel perforation. Involvement of the kidney manifested with a doubling of the recipient's baseline serum creatinine level. Significant lowering of the tacrolimus dose resulted in healing of the small bowel ulcers and return to her baseline level of renal function. Therefore, it is important to note that, in transplant recipients, TMA with microvascular occlusion may affect extrarenal sites. In small bowel transplant recipients, the result might be ischemic ulcers in the graft and eventual bowel perforation.",
keywords = "Combined liver-small bowel transplantation, Hemolytic uremic syndrome, Thrombotic microangiopathy",
author = "Abhinav Humar and Jose Jessurun and Sharp, {Harvey L.} and Gruessner, {Rainer W G}",
year = "1998",
month = "12",
language = "English (US)",
volume = "12",
pages = "600--601",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Thrombotic microangiopathy after liver-small bowel transplant

AU - Humar, Abhinav

AU - Jessurun, Jose

AU - Sharp, Harvey L.

AU - Gruessner, Rainer W G

PY - 1998/12

Y1 - 1998/12

N2 - We herein report the first case of immunosuppression-associated thrombotic microangiopathy (TMA) in which an extrarenal graft was primarily affected by the characteristic microvascular lesions. Although TMA is a well-known complication of cyclosporine (CSA) or tacrolimus therapy in renal and extrarenal (liver, heart, lung) transplant recipients, the kidney (transplanted or native) is typically the site primarily affected. We describe a combined liver-small bowel transplant recipient who developed tacrolimus-associated TMA that affected both her transplanted small bowel and her native kidneys. Involvement of the bowel, with evidence of microvascular occlusion on biopsy, led to the development of ischemic mucosal ulcers and eventual bowel perforation. Involvement of the kidney manifested with a doubling of the recipient's baseline serum creatinine level. Significant lowering of the tacrolimus dose resulted in healing of the small bowel ulcers and return to her baseline level of renal function. Therefore, it is important to note that, in transplant recipients, TMA with microvascular occlusion may affect extrarenal sites. In small bowel transplant recipients, the result might be ischemic ulcers in the graft and eventual bowel perforation.

AB - We herein report the first case of immunosuppression-associated thrombotic microangiopathy (TMA) in which an extrarenal graft was primarily affected by the characteristic microvascular lesions. Although TMA is a well-known complication of cyclosporine (CSA) or tacrolimus therapy in renal and extrarenal (liver, heart, lung) transplant recipients, the kidney (transplanted or native) is typically the site primarily affected. We describe a combined liver-small bowel transplant recipient who developed tacrolimus-associated TMA that affected both her transplanted small bowel and her native kidneys. Involvement of the bowel, with evidence of microvascular occlusion on biopsy, led to the development of ischemic mucosal ulcers and eventual bowel perforation. Involvement of the kidney manifested with a doubling of the recipient's baseline serum creatinine level. Significant lowering of the tacrolimus dose resulted in healing of the small bowel ulcers and return to her baseline level of renal function. Therefore, it is important to note that, in transplant recipients, TMA with microvascular occlusion may affect extrarenal sites. In small bowel transplant recipients, the result might be ischemic ulcers in the graft and eventual bowel perforation.

KW - Combined liver-small bowel transplantation

KW - Hemolytic uremic syndrome

KW - Thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=0031784143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031784143&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 600

EP - 601

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -